Introduction: For over 40 years, ebolaviruses have been responsible for sporadic outbreaks of severe and often fatal hemorrhagic fever in humans and nonhuman primates across western and central Africa. In December 2013, an unprecedented Ebola virus (EBOV) epidemic began in West Africa and resulted in the largest outbreak to date. The past and current epidemics in West Africa and the Democratic Republic of the Congo has focused attention on the potential vaccine platforms developed over the past 20 years.Areas covered: This review summarizes the extraordinary progress using a variety of vaccination platforms including DNA, subunit, and several viral vector approaches, replicating and non-replicating, incorporating the primary antigen of EBOV, the glycoprotein. These vaccine constructs have shown varying degrees of protective efficacy in the 'gold-standard' nonhuman primate model for EBOV infections and were immunogenic in human clinical trials.Expert commentary: A number of these vaccine platforms have moved into phase III clinical trials over the past years and with the recent approval of the first EBOV vaccine in the European Union and the USA there is a strong potential to prevent future outbreaks/epidemics of EBOV infections on the scale of the West African epidemic.

中文翻译：

---

埃博拉病毒糖蛋白及其跨多个疫苗平台的免疫反应。

简介：40多年来，埃博拉病毒一直导致整个非洲西部和中部人类和非人类灵长类动物发生严重且经常致命的出血热散发。2013年12月，西非爆发了史无前例的埃博拉病毒（EBOV）疫情，并导致了迄今为止最大规模的暴发。西非和刚果民主共和国过去和现在的流行病都将注意力集中在过去20年开发的潜在疫苗平台上。涵盖的领域：本综述总结了使用各种疫苗接种平台（包括DNA，亚基，和几种病毒载体方法，复制的和非复制的，结合了EBOV的主要抗原，即糖蛋白。这些疫苗构建物在“